NewsStackNewsStack
Daily Brief: Which companies are hyping vs delivering: red flags, real signals and repeat offenders, free daily.

ZYME

NASDAQ:ZYMENASDAQ
7 announcements
Credibility Score56%
Zymeworks Announces Participation in Upcoming Investor Conferences
Routineunclear

Zymeworks schedules investor conference appearances but discloses no new financial or clinical data.

19 Nov 2026, 11:00 UTC
▼
Zymeworks Announces $200 Million Share Repurchase Authorization
OverhypedModerate hypeunclear

Zymeworks authorizes $200 million buyback, expects $140 million spent by 2028.

16 Nov 2026, 11:00 UTC
▼
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
OverhypedModerate hypeunclear

ZW191 shows strong Phase 1 efficacy but faces long-term development and funding hurdles.

24 Oct 2026, 06:30 UTC
▼
Zymeworks to Acquire Theravance Biopharma, Inc.
OverhypedModerate hypeimproving

Big promises, big price tag—real payoff is years away and far from guaranteed.

29 Jun 2026, 10:16 UTC
▼
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
OverhypedModerate hypeunclear

Promising early cancer data, but high toxicity and no financials mean caution is warranted.

14 Jun 2026, 22:14 UTC
▼
Zymeworks Announces Participation in Upcoming Investor Conferences
OverhypedModerate hypeunclear

Zymeworks offers big biotech promises but delivers little hard evidence for investors today.

13 May 2026, 10:14 UTC
▼